# An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

> **NCT05037851** · PHASE2 · COMPLETED · sponsor: **Pulmocide Ltd** · enrollment: 102 (actual)

## Conditions studied

- Pulmonary Aspergillosis

## Interventions

- **DRUG:** Opelconazole
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT05037851
- **Lead sponsor:** Pulmocide Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-19
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-11-13
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05037851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05037851, "An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05037851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*